Revance to Participate in Upcoming Investor Conferences
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and
underserved therapeutic conditions, today announced that the company will participate in two upcoming investor conferences.
President and Chief Executive Officer, Dan Browne, is scheduled to present at the Cowen and Company 38th Annual
Health Care Conference in Boston, MA on Tuesday, March 13 at 8:40am ET.
Chief Financial Officer and Chief Business Officer, Lauren Silvernail, is scheduled to participate in a fireside chat discussion
at the Barclays Capital Healthcare Conference in Miami, FL on Thursday, March 15 at 8:00am ET.
Interested parties can access the live audio webcasts for both conferences from the Investor Relations section of the company's
website at www.revance.com. The webcast replays will be available after the conclusion of the live presentations for
approximately 30 days.
About Revance Therapeutics, Inc.
Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved
therapeutic conditions, including muscle movement disorders and pain. The company's lead drug candidate, DaxibotulinumtoxinA for
Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis, with
the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide
technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide
technology, including injectable and topical formulations of daxibotulinumtoxinA. More information on Revance may be found at
www.revance.com.
"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
INVESTORS
Revance Therapeutics, Inc.
Jeanie Herbert, 714-325-3584
jherbert@revance.com
or
Burns McClellan, Inc.
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com
or
MEDIA
General Media:
TOGORUN
Mariann Caprino, 917-242-1087
m.caprino@togorun.com
or
Trade Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20180306005219/en/